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Crystal Structures of Two FGF-FGFR
Complexes Reveal the Determinants of
Ligand-Receptor Specificity
There are no direct FGF-FGF interactions in this dimer.
A positively charged canyon is formed by the heparin
binding sites of FGFs and FGFRs in this dimer. Heparin
is postulated to bind in this canyon and bridge the two
1:1 FGF-FGFR complexes (Plotnikov et al., 1999).
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New York, New York 10016 FGF-FGFR specificity is an essential mechanism in the
regulation of FGF responses and is achieved primarily
through alternative splicing in the second half of D3 in
FGFRs. This is best documented for FGFR2. FGFR2 andSummary
keratinocyte growth factor receptor (KGFR) differ only
in the second half of D3. In FGFR2, the second half ofTo elucidate the structural determinants governing
specificity in fibroblast growth factor (FGF) signaling, D3 is encoded by exon IIIc, whereas in KGFR this region
is encoded by exon IIIb. FGFR2 binds FGF1 and FGF2we have determined the crystal structures of FGF1
and FGF2 complexed with the ligand binding domains but does not bind FGF7 (KGF). In contrast, KGFR binds
FGF1 and FGF7 but binds FGF2 with much lower affinity(immunoglobulin-like domains 2 [D2] and 3 [D3]) of FGF
receptor 1 (FGFR1) and FGFR2, respectively. Highly (Dell and Williams, 1992; Miki et al., 1992; Yayon et al.,
1992). Although alternative splicing is critical in modulat-conserved FGF-D2 and FGF-linker (between D2-D3)
interfaces define a general binding site for all FGF- ing ligand-receptor specificity, analogous splice vari-
ants of different FGFRs also exhibit differential ligandFGFR complexes. Specificity is achieved through in-
teractions between the N-terminal and central regions binding specificity. For example, FGF2 binds FGFR1(IIIc)
and FGFR2(IIIc) with comparable affinity but bindsof FGFs and two loop regions in D3 that are subject
to alternative splicing. These structures provide a mo- weakly to FGFR3(IIIc) (Chellaiah et al., 1999). FGF1 binds
to all FGFRs irrespective of alternative splicing (Ornitzlecular basis for FGF1 as a universal FGFR ligand and
for modulation of FGF-FGFR specificity through pri- et al., 1996).
In this report, we describe the crystal structures ofmary sequence variations and alternative splicing.
two FGF-FGFR complexes: FGF1 in complex with
FGFR1 and FGF2 in complex with FGFR2. By comparingIntroduction
these two structures and the previously described struc-
ture of FGF2-FGFR1 (Plotnikov et al., 1999), valuableThe mammalian fibroblast growth factor (FGF) family
insights into the molecular mechanisms that governconsists of at least 19 structurally related polypeptides
FGF-FGFR binding specificity have been obtained.(FGF1-19), which play key roles in morphogenesis, de-
velopment, angiogenesis, and wound healing (reviewed
Results and Discussionby Burgess and Maciag, 1989; Basilico and Moscatelli,
1992; Naski and Ornitz, 1998). These FGF-stimulated
Structure Determinationprocesses are mediated by four FGF receptor tyrosine
The ligand binding domains of FGFR1 and FGFR2, con-kinases (FGFR1±4). FGFRs are composed of an extracel-
sisting of Ig-like domains 2 (D2) and 3 (D3), were ex-lular ligand binding portion consisting of three immuno-
pressed in E. coli. Both proteins were found in inclusionglobulin (Ig)-like domains (D1, D2, and D3), a single
bodies and were solubilized using denaturating agentstransmembrane helix, and a cytoplasmic portion that
and refolded in vitro. The refolded proteins were purifiedcontains protein tyrosine kinase activity. Ligand binding
using ligand-affinity chromatography, and the 1:1 FGF1-and specificity reside in D2, D3, and the linker that con-
FGFR1 and FGF2-FGFR2 complexes were isolated bynects them (reviewed by Johnson and Williams, 1993;
size-exclusion chromatography. Crystallization trialsJaye et al., 1992).
with these complexes produced triclinic crystals.FGFR activation and signaling are dependent on FGF-
The crystal structures of FGF1-FGFR1 and FGF2-induced dimerization, a process that also requires cell
FGFR2 were solved by molecular replacement (see thesurface heparin or heparan sulfate proteoglycans (Yayon
Experimental Procedures) and were refined at 2.8 andet al., 1991; Ornitz et al., 1992; Spivak-Kroizman et al.,
2.2 AÊ , respectively. The atomic model for FGF1-FGFR11994). A model has emerged from the recent crystal
consists of two FGF1 molecules, two FGFR1 molecules,structure of FGF2 complexed with the ligand binding
and four sulfate ions. The atomic model for FGF2-FGFR2domain of FGFR1 to explain how FGFs in concert with
consists of four FGF2 molecules, four FGFR2 molecules,heparin induce FGFR dimerization and activation (Plot-
four sulfate ions, and 263 water molecules. Data collec-nikov et al., 1999). In the crystal structure, two 1:1
tion and refinement statistics are given in Table 1.FGF:FGFR complexes form a 2:2 dimeric FGF-FGFR
assemblage, which is partially stabilized by direct FGFR-
Description of Structures of FGF-FGFR ComplexesFGFR interactions and by interactions between FGF in
The overall structures of the FGF1-FGFR1 and FGF2-one 1:1 complex and FGFR in the adjoining complex.
FGFR2 complexes (Figure 1) are similar to the previously
determined FGF2-FGFR1 structure (Plotnikov et al.,³ To whom correspondence should be addressed (e-mail: mohammad@
saturn.med.nyu.edu). 1999). The three-dimensional folds of D2 and D3 in the
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Table 1. Summary of Crystallographic Analysis
Data Collection Statistics
Structure Resolution (AÊ ) Reflections (Total/Unique) Completeness (%) Rsyma (%) Signal (,I/sI.)
FGF1-FGFR1 25.0±2.8 49288/22330 97.9 (90.5)b 8.3 (22.6)b 8.6
FGF2-FGFR2 25.0±2.2 206913/93440 96.3 (87.8)b 4.2 (24.1)b 16.3
Refinement Statisticsc
Root-Mean-Square Deviations
Structure Resolution (AÊ ) Reflections Rcryst/Rfreed (%) Bonds (AÊ ) Angles (8) B-factorse (AÊ 2)
FGF1-FGFR1 25.0±2.8 21539 24.9/30.0 0.009 1.5 2.3
FGF2-FGFR2 25.0±2.2 84816 24.8/27.3 0.007 1.3 1.0
a Rsym 5 100 3 ShklSi IIi(hkl) 2 ,I(hkl).I/ShklSi Ii(hkl).
b Value in parentheses is for the highest resolution shell: 2.90-2.80 AÊ (FGF1-FGFR1), 2.28-2.20 AÊ (FGF2-FGFR2).
c Atomic model: 4963 protein atoms and four SO4 ions (FGF1-FGFR1) and 9818 protein atoms, four SO4 ions, and 263 water molecules (FGF2-
FGFR2).
d Rcryst/free 5 100 3 Shkl IIFo(hkl)I 2 IFc(hkl)II/Shkl IFo(hkl)I, where Fo (.0s) and Fc are the observed and calculated structure factors, respectively.
5% of the reflections were used for calculation of Rfree.
e For bonded protein atoms.
FGF1-FGFR1 and FGF2-FGFR2 structures resemble et al., 1999), this segment is also well ordered and inter-
acts with the ligand. At the C-terminal end of this seg-that of the Ig I-set prototype member telokin, in which
a b sandwich is formed by two layers of b sheets (Holden ment in the FGF2-FGFR1 structure, a short a helix (aD)-
was assigned by PROCHECK (Laskowski et al., 1993).et al., 1992). A highly conserved disulfide bond is buried
in the hydrophobic cores of D2 and D3, bridging the two In the present FGF2-FGFR2 structure, the polypeptide
chain at the C-terminal end adopts a similar conforma-b sheets. In both structures, the bC-bC9 loop in D3 is
disordered (Figure 1). tion but is not designated an a helix.
As reported previously, both FGF1 and FGF2 adoptThe main difference between the structures of FGF1-
FGFR1 and FGF2-FGFR2 is the conformation of the seg- a b trefoil fold that consists of three copies of a four-
stranded antiparallel b sheet (Figure 1) (reviewed byment connecting bC9 and bE in D3 (Figure 1). In the
FGF2-FGFR2 structure, this segment is well ordered and Faham et al., 1998). Superpositions of receptor-bound
FGF1 and FGF2 with free FGF1 and FGF2 indicate thatinteracts with FGF2, while in the FGF1-FGFR1 structure,
this segment is disordered and is not included in the no significant conformational changes occur in FGF1
and FGF2 upon receptor binding. As in the crystal struc-atomic model. In the FGF2-FGFR1 structure (Plotnikov
Figure 1. Ribbon Diagrams of the FGF1-
FGFR1 and FGF2-FGFR2 Complexes
The Ig-like domains 2 (D2) and 3 (D3) are
shown in green and cyan, respectively. The
short linker that connects D2 and D3 is col-
ored gray. FGF1 and FGF2 are shown in or-
ange. The secondary structure assignments
for FGFR1 and FGFR2 were obtained with the
program PROCHECK (Laskowski et al., 1993).
The b strands for D2 and D3 are labeled
according to the strand nomenclature for the
canonical I-set member telokin. The helix be-
tween bA and bA9, gA, is a 310 helix. In both
FGF1-FGFR1 and FGF2-FGFR2 structures,
the bC-bC9 loops in D3 are disordered. In
addition, most of the segment between bC9
and bE in D3 of FGF1-FGFR1 is disordered
as well. In the FGF2-FGFR2 structure, this
segment is well ordered and is colored pur-
ple. The amino and carboxy termini are de-
noted by NT and CT. The disulfide bonds in
D2 and D3 are shown in ball-and-stick render-
ing with sulfur atoms colored yellow. The b
strands of FGF1 are labeled from 1 to 12 ac-
cording to published nomenclature (Faham
et al., 1998). This figure was created using
the programs Molscript (Kraulis, 1991) and
Raster3D (Merrit and Bacon, 1997).
Crystal Structures of FGF-FGFR Complexes
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Figure 2. Space-Filling Models of the FGF1-
FGFR1 and FGF2-FGFR2 Complexes
The coloring for D2, D3, the linker, and FGFs
is the same as in Figure 1. The view is the
same as in Figure 1. To better visualize the
binding interfaces on FGFs and on FGFRs,
the molecules are pulled away from each
other and rotated 908 about the vertical axis
as indicated (left and right panels). Residues
in FGF1 and FGF2 are colored with respect
to the FGFR regions with which they interact.
FGF1 and FGF2 residues that interact with
D2 are colored green, residues that interact
with the linker region are colored gray, and
residues that interact with D3 are colored
cyan. FGF2 residues that interact with the
bC9-bE segment (shown in purple) of FGFR2
are colored red. The residues in FGFR1 and
FGFR2 that interact with FGF1 and FGF2, re-
spectively, are colored orange. In addition, in
the FGF2-FGFR2 structure, receptor residues
in the bC9-bE segment that contact FGF2 are
in red. Ligand and receptor residues are con-
sidered to be in the FGF-FGFR interface if at
least one pair of atoms (side chain or main
chain) has an interatomic distance of 3.8 AÊ
or less. This figure was created using the pro-
grams Molscript and Raster3D.
tures of free FGF1 and FGF2, ordered sulfate ions are Tyr-103 makes a water-mediated hydrogen bond with
the backbone of Ala-168.found in the heparin binding sites of receptor-bound
FGF1 and FGF2. The ligands in both the FGF1-FGFR1 The observed interactions between FGF2 and FGFR2
in the FGF2-D2 interface are entirely consistent withand FGF2-FGFR2 structures interact with residues in
D2 and D3 of the receptors and in the linker connecting mutagenesis studies on FGF2. It was demonstrated that
individual replacements with alanine of Tyr-24, Tyr-103,the two domains (Figure 2).
Leu-140, and Met-140, all of which are located in the
FGF2-D2 interface (Figure 3A), result in a large decreaseThe FGF-D2 Interface
The interface between FGF and D2 in both complexes in receptor binding affinity (Springer et al., 1994). The
FGF-D2 interfaces in the structures of FGF2-FGFR2 andis mainly hydrophobic (Figures 3A and 3B). A solvent-
exposed hydrophobic surface in FGF packs against a FGF1-FGFR1 are very similar (Figures 3A and 3B). FGF2
and FGF1 differ in only two positions in the FGF-D2highly conserved hydrophobic surface at the bottom of
D2 in FGFR. In the FGF2-FGFR2 structure, Tyr-24, Leu- interface: Met-142 in FGF2 is replaced by Leu-135 in
FGF1, and Asn-102 in FGF2 is substituted with His-93140, and Met-142 in FGF2 make hydrophobic contacts
with Ala-168 in FGFR2. Leu-140, Tyr-103, and the ali- in FGF1. The latter substitution may not affect the bind-
ing of FGF1 to D2, since only the aliphatic portion ofphatic portion of the Asn-102 side chain in FGF2 make
hydrophobic contacts with Pro-170 in FGFR2. Phe-31 the His-93 side chain is observed to interact with FGFR1.
of FGF2 is engaged in hydrophobic interactions with
Leu-166 of FGFR2. Leu-166, Ala-168, and Pro-170 of The FGF-Linker Interface
Interactions between FGF1 and FGF2 and the D2-D3FGFR2 are located in bA9 at the bottom of D2. Val-249,
located at the C-terminal end of bG in D2, is also in the linker of FGFR1 and FGFR2 are mediated mainly via
hydrogen bonds (Figures 3C and 3D). In the FGF2-FGF2-D2 interface and interacts with Leu-140 and Met-
142 in FGF2. Several hydrogen bonds further fortify the FGFR2 structure, an invariant arginine located in the D2-
D3 linker, Arg-251, forms hydrogen bonds with the sidemainly hydrophobic FGF2-D2 interface: the hydroxyl
group of Tyr-24 in FGF2 forms two hydrogen bonds with chain of Asn-104 and the backbone carbonyl oxygen of
Asn-102 in FGF2. Replacement of Asn-104 in FGF2 withbackbone atoms of Leu-166 and Ala-168 in FGFR2, and
Cell
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Figure 3. Detailed Interactions between FGF and FGFR in the FGF-D2 and FGF-Linker Interfaces
(A) Stereo view of the hydrophobic interface between FGF2 and D2 of FGFR2.
(B) Stereo view of the hydrophobic interface between FGF1 and D2 of FGFR1.
(C) Stereo view of the conserved network of hydrogen bonds between FGF2 and FGFR2 in the vicinity of Arg-251 in the D2-D3 linker.
(D) Stereo view of the network of hydrogen bonds between FGF1 and FGFR1 in the vicinity of Arg-250 in the D2-D3 linker. Only side chains
of interacting residues are shown. At the right side of each stereo pair, a view of the whole structure in the exact orientation as in stereo
views is shown, and the region of interest is highlighted. Color coding is the same as in Figure 1: FGF1 and FGF2 in orange, D2 in green, D3
in cyan, and the linker in gray. Oxygen atoms are colored red, nitrogen atoms blue, and carbon atoms have the same coloring as the molecules
to which they belong. Dotted lines represent hydrogen bonds. This figure was created using the programs Molscript and Raster3D.
an alanine causes a 400-fold reduction in the binding at this position, whose side chain is shorter than aspara-
gine. One would predict that these FGFs will not formaffinity of FGF2 for FGFR1 (Zhu et al., 1997), verifying
the importance of the observed interaction between a direct hydrogen bond with the arginine in the D2-D3
linker and therefore will exhibit lower binding affinityFGF2 and the D2-D3 linker.
An alignment of the 19 available FGF sequences toward FGFRs. Interestingly, FGF11, FGF12, FGF13, and
FGF14 have a valine in place of Asn-104 of FGF2 (Figureshows that the majority of FGFs have an asparagine in
the position corresponding to Asn-104 of FGF2 (Figure 6). This substitution is expected to cause a strong de-
crease in FGFR binding.6). However, FGF8, FGF17, and FGF18 have a threonine
Crystal Structures of FGF-FGFR Complexes
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Figure 4. Detailed Interactions between FGF and FGFR in the FGF-D3 Interfaces
(A) Stereo view of the interface between FGF2 and the bF-bG loop of D3 in the FGF2-FGFR2 structure.
(B) Stereo view of the interface between N-terminal sequences (prior to b1) of FGF2 and D3 in the FGF2-FGFR2 structure.
(C) Stereo view of the interface between FGF2 and the bC9-bE segment (shown in purple) of D3 in the FGF2-FGFR2 structure.
(D) Stereo view of the interface between FGF1 and D3 in the FGF1-FGFR1 structure. At the right side of each stereo pair, a view of the whole
structure in the exact orientation as in stereo views is shown, and the region of interest is highlighted. Only side chains of interacting residues
are shown. Color coding is the same as in Figure 3. Dotted lines represent hydrogen bonds. This figure was created using the programs
Molscript and Raster3D.
The hydrogen bond between Arg-251 and FGF2 exists freedom of the guanidinium group of Arg-251 and amide
group of Asn-104 (Figure 3C). These interactions mayin a hydrophobic pocket composed of the aliphatic side
chains of highly conserved Val-249 and Pro-253 in increase the ligand binding affinity by lowering the en-
tropy of FGF-FGFR complex formation. Indeed, substi-FGFR2 and Leu-98 and Pro-141 in FGF2 (Figure 3C).
This hydrophobic environment will likely enhance the tution of Tyr-106 with a phenylalanine in FGF2 caused
a 5-fold reduction in receptor binding (Zhu et al., 1995).strength of this hydrogen bond. Moreover, the intramo-
lecular hydrogen bonds between Arg-251 and the invari- A nearly identical set of interactions is observed in
the FGF-linker interface in the FGF1-FGFR1 (Figure 3D)ant Asp-283 in FGFR2 and between Asn-104 and Tyr-
106 in FGF2 probably serve to restrict the rotational and FGF2-FGFR2 (Figure 3C) structures. Moreover, a
Cell
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sequence alignment of all known members of the FGF in FGF2 cause a 10- and 80-fold reduction, respectively,
and FGFR families shows that residues in FGF and FGFR in receptor binding affinity (Zhu et al., 1998).
that constitute the FGF-D2 and FGF-linker interfaces In the FGF1-FGFR1 structure, however, the bC9-bE
are conserved among the four mammalian FGFRs (Fig- loop is disordered, probably due to the lack of interac-
ure 5A) and the 19 FGFs (Figure 6). Thus, based on our tion between FGF1 and this loop (Figure 1). As a result
structures and the sequence alignment, we propose that of this difference, the total accessible surface area bur-
the FGF-D2 and FGF-linker interfaces described above ied in the FGF1-FGFR1 complex is 2200AÊ 2 as compared
represent a general binding interface for all FGF-FGFR to 2700AÊ 2 in the FGF2-FGFR2 complex. A potential ex-
complexes. planation for the observed disorder of the bC9-bE seg-
ment in the FGF1-FGFR1 crystal structure can be ob-
The FGF-D3 Interface tained by comparing the FGF1 and FGF2 sequences.
Interactions between FGF and D3 occur at the upper Two residues in FGF2 that interact with the bC9-bE loop,
part of D3. These interactions are mediated mainly by Gln-56 and Val-88, are substituted in FGF1 with Ser-47
the bB9-bC, bC9-bE, and bF-bG loops of FGFRs. While and Pro-79, which are less capable of interacting with
residues in the bB9-bC are highly conserved, the amino this loop. Thus, loss of these interactions may increase
acid sequences of the bC9-bE and bF-bG loops are the flexibility of the bC9-bE segment, leading to a disor-
highly divergent among FGFRs (Figure 5B). Notably, al- dered bC9-bE loop. Based on this structural analysis,
ternative splicing occurs at the junction between bC9 we propose that FGF1 does not engage in any specific
and the bC9-bE loop. Thus, the bC9-bE and bF-bG loops contacts with the bC9-bE loop. This would provide a
are located in the second half of D3, which is subject potential explanation as to why FGF1 functions as a
to alternative splicing. FGF-D3 interactions involve the universal ligand for all known alternatively spliced forms
most divergent regions of FGFs, including the N-terminal of FGFRs.
segment, outside of the b trefoil core (prior to b1), and It is likely that the bC9-bE loop exists in several differ-
the central segment consisting of b4 and the b4-b5 loop. ent conformations and that interactions with different
In contrast to the FGF-D2 interface, which is dominated FGFs will modify its structure. In the crystal structures
by hydrophobic interactions, most of the interactions in of FGF2-FGFR2 (reported here) and FGF2-FGFR1 (Plot-
the FGF-D3 interface are mediated by hydrogen bonds. nikov et al., 1999), the bC9-bE segment forms a small
Moreover, many of the hydrogen bonds between FGF hydrophobic core by means of interactions between
and D3 are water mediated. The polar nature of this three residues in this region, Ala-315, Thr-319, and Ile-
FGF-D3 interface is consistent with this interface playing 324, along with Ile-288 located in bC in D3. It is conceiv-
a critical role in FGF-FGFR specificity. able that in the unoccupied receptors, the side chains
Conserved interactions between FGF2 and the bB9- of these residues are not sufficiently hydrophobic to
bC loop in D3 are mediated by four hydrogen bonds form a stable core. In the occupied receptors, interac-
(one direct, three water mediated) between an FGF- tions with FGF2 may facilitate the positioning of these
invariant glutamate, Glu-96 in FGF2, and FGFR-invariant
hydrophobic residues, leading to formation of a stable
Gln-285 in the bB9-bC loop of D3 (Figures 3C and 4A).
structure.
A water-mediated hydrogen bond between the side
The crystal structure of an FGF1-FGFR2 complex was
chain of Asn-104 and the backbone carbonyl oxygen of
recently reported (Stauber et al., 2000). In contrast toAsp-283 is also made in this interface (Figure 3C). The
the FGF1-FGFR1 structure described here, the bC9-bEimportance of Glu-96 for FGFR binding was confirmed
loop in the FGF1-FGFR2 structure is ordered and makesby a 1000-fold reduction in receptor binding for an FGF2
several contacts with FGF1. Based on this structure,mutant containing an alanine in place of Glu-96 (Zhu et
changes in the primary sequence of the bC9-bE loop (asal., 1995).
a result of alternative splicing) would presumably affectIn contrast to the interface between FGF and the bB9-
FGF1 binding, which is not consistent with the well-bC loop, the interactions between FGF and the bC9-
documented universal binding characteristics of FGF1bE loop in D3 are highly variable. In the FGF2-FGFR2
(Ornitz et al., 1996).structure, the bC9-bE loop is well ordered and makes
The bC9-bE loop of all known FGFRs, with the excep-several specific contacts with residues in b4 of FGF2
tion of FGFR3(IIIb), contains a highly conserved potential(Figure 4C). A total of five hydrogen bonds are formed
N-glycosylation site (Asn-318 in FGFR2). We have con-at the interface between FGF2 and the bC9-bE segment
firmed that Asn-318 is glycosylated in the extracellularin the FGF2-FGFR2 structure (Figure 4C). Two hydrogen
domain of FGFR2 when expressed in insect cells. In thebonds are formed between the side chain of Gln-56 in
crystal structure of FGF1-FGFR2 (Stauber et al., 2000),FGF2 and Asp-321 in FGFR2, and two hydrogen bonds
the (nonglycosylated) side chain of Asn-318 makes twoare made between the side chain of Glu-58 in FGF2 and
hydrogen bonds with FGF1. This unexpected structuralbackbone atoms of Val-317 and Asn-318 in FGFR2. A
feature, along with the disparity in FGF1 interactionsfifth hydrogen bond is made between the backbone of
with D3, led us to consider whether the interactionsAla-57 in FGF2 and the side chain of Asp-321 via an
between the bC9-bE loop and FGF1 in the FGF1-FGFR2ordered water molecule. Hydrophobic contacts be-
structure could be due to crystal packing and thus nottween the side chain of Val-317 in FGFR2 and the side
reflect the situation in vivo.chains of Tyr-73, Val-88, and Phe-93 in FGF2 fortify this
Analysis of the relative disposition of D2 and D3 in allinterface (Figure 4C). Mutagenesis experiments support
the FGF-FGFR structures demonstrates that the anglethe involvement of both Val-88 and Phe-93 in receptor
binding. Replacement of Val-88 and Phe-93 with alanine between D2 and D3 is not dictated solely by the contacts
Crystal Structures of FGF-FGFR Complexes
419
Figure 5. Structure-Based Sequence Align-
ment of the Ligand Binding Domains of Hu-
man FGF Receptors
(A) Structure-based sequence alignment of
D2 and D2-D3 linker. (B) Structure-based se-
quence alignment of D3. The secondary
structure assignment for FGFR2 was ob-
tained using the program PROCHECK
(Laskowski et al., 1993). The location and
length of the strands and helices are shown
on the top of the sequence alignment. The
letter ªgº denotes a residue in a 310 helix. Only
310 helices comprising four or more residues
are indicated. A period indicates sequence
identity to FGFR2. A dash represents a gap
introduced to optimize the alignment. FGFR
residues that interact with FGF2 are colored
yellow. FGFR residues in the bC9-bE segment
that contact FGF2 are in red. Only receptor
residues whose side chain or main chain
atoms are within 3.8 AÊ of FGF2 are colored.
between the two domains and the ligand; crystal pack- the bC9-bE hydrophobic core (Ala-315, Thr-319, and Ile-
324) are replaced by residues in KGFR (Ser-315, Ser-ing also affects the relative disposition of the two do-
319, and Ala-322) that are less likely to form a hydropho-mains. Although the FGF1-FGFR1 (reported here) and
bic core (Figure 5B). Thus, as the result of these changes,FGF1-FGFR2 (Stauber et al., 2000) structures feature a
the bC9-bE loop in KGFR will not be able to interactcommon ligand, superimposition of the Ca atoms of D2
efficiently with FGF2. This proposal is supported byreveals an 88 difference in the relative placement of D3
binding experiments of FGF2 to a mutant FGFR2 into D2 in the two structures. As a consequence, the bC9-
which its bC9-bE loop is replaced with the correspondingbE loop in the FGF1-FGFR2 structure is closer to the
region from KGFR. The affinity of FGF2 toward this mu-ligand. It is therefore conceivable that the interactions
tant is reduced by an order of magnitude (Gray et al.,between the bC9-bE loop and FGF1 in this structure are
1995). Conversely, amino acid insertion or substitutiondue to lattice interactions. In the FGF1-FGFR1 structure,
in the bC9-bE loop of KGFR specifically abolished KGFthe bC9-bE loop is disordered in both complexes in the
binding without affecting FGF1 binding (Wang et al., 1995).asymmetric unit, providing two independent cases in
Moreover, replacement of the bC9-bE loop in FGFR1(IIIc)
which the bC9-bE loop does not engage FGF1.
with that of KGFR conferred upon the chimeric FGFR1(IIIc)
receptor the ability to bind KGF (Wang et al., 1999), while
wild-type FGFR1(IIIc) does not bind KGF.
Structural Basis for the Role of Alternative Splicing These data indicate that there may be steric clashes
in FGF Binding Specificity between KGF and the bC9-bE segment in FGFR2(IIIc)
Role of the bC9-bE Segment resulting in the reduced affinity of KGF to FGFR2(IIIc).
Our structural data provide a molecular basis for under- Conversely, the bC9-bE segment of KGFR may interact
standing how alternative splicing switches specificity. more efficiently with KGF. The latter hypothesis is sup-
As mentioned above, alternative splicing occurs at the ported by the finding that a synthetic peptide derived
end of bC9, resulting in major changes in the primary from KGFR encompassing the bC9-bE segment com-
sequence as well as in the length of the bC9-bE loop. petes specifically with the binding of KGF to KGFR (Bot-
For example, the amino acid sequence of the bC9-bE taro et al., 1993). Validation of these structure-based
loop in KGFR/FGFR2(IIIb) has seven substitutions and proposals, however, awaits a crystal structure of KGF
is two amino acids shorter than the corresponding re- in complex with KGFR.
gion in FGFR2(IIIc) (Figure 5B). Significantly, the three Our structural findings are also consistent with the
identification of a central segment in KGF (residues 91±residues in FGFR2(IIIc) that participate in formation of
Cell
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Figure 6. Structure-Based Sequence Align-
ment of FGFs
Sequence alignment was performed using
the CLUSTALW program (Thompson et al.,
1994). All of the FGFs used in this alignment
are from human, with the exception of FGF15,
for which only the mouse sequence is avail-
able. The secondary structure assignment is
according to the published nomenclature,
with the b strands labeled from 1 through
12 (Faham et al., 1998). The location and the
length of the b strands are shown on the top
of the sequence alignment. FGF residues are
colored with respect to the region on FGFR
with which they interact: FGF residues that
interact with D2 are colored green, residues
that interact with the linker region are colored
gray, and residues that interact with D3 are
colored cyan. FGF residues that interact with
the bC9-bE segment in D3 are colored red. A
period indicates sequence identity to FGF2. A
dash represents a gap introduced to optimize
the alignment. A tilde at the C-terminal end
of an FGF sequence indicates that the se-
quence is truncated. A star indicates that
numbering does not start at the initiation me-
thionine. Residue numbering for FGF1 and
FGF2 is according to Zhu et al. (1991) and
Springer et al. (1994), respectively. FGF resi-
dues shown by mutagenesis to be important
for receptor binding are checkmarked.
110) necessary for specific recognition and activation water-mediated hydrogen bonds with Glu-96 and Leu-
98 of FGF2 (Figure 4A). A water-mediated hydrogenof KGFR (Reich-Slotky et al., 1995). This region mainly
bond between Gly-345 in FGFR2 and Gly-61 in FGF2,corresponds to b4 and the b4-b5 loop in FGF2 (Figure
and a direct hydrogen bond between the backbone of6), which in the crystal structure of FGF2-FGFR2 make
Asn-346 in FGFR2 and the side chain of Arg-60 in FGF2,specific contacts with the bC9-bE and bF-bG loops in
provide additional contacts in this region (Figure 4A).D3, respectively (Figures 4C and 4A).
Arg-60 and Gly-61 are located in the b4-b5 loop in FGF2The observed interactions between FGF and the bC9-
(Figure 6). Comparison of amino acid sequences showsbE loop (Figure 4C) afford a plausible explanation as to
that FGFs display considerable sequence variation atwhy similarly spliced variants of FGFRs exhibit differen-
the position of Arg-60 in FGF2. Gly-61, though, is highlytial binding specificity. It was shown that FGF2 binds
conserved in FGFs (Figure 6). While the bF-bG loop isstrongly to FGFR1(IIIc) and FGFR2(IIIc) but poorly to
invariant in the IIIc forms of FGFRs, alternative splicingFGFR3(IIIc) and FGFR4 (Vainikka et al., 1992; Ron et al.,
results in two amino acid substitutions in this loop (Fig-1993; Chellaiah et al., 1999). A survey of amino acid
ure 5B). For example, Gly-345 and Ser-347 of FGFR2(IIIc)sequences in the bC9-bE loop of these receptors shows
are replaced by Ser-342 and Tyr-345 in KGFR/FGFR2(I-that the bC9-bE loop in FGFR4, as in KGFR, is two amino
IIb). Analysis of the FGF2-FGFR2 structure shows thatacids shorter than the corresponding loop in the IIIc
replacement of Ser-347 in FGFR2 with a tyrosine is dis-form of FGFR1-3 (Figure 5B). Due to this deletion, it is
advantageous with regard to interaction with FGF2. Thispossible that this loop in FGFR4 cannot interact effi-
substitution will result in the loss of the water-mediatedciently with FGF2. The bC9-bE loop in FGFR3(IIIc) differs
hydrogen bond between Ser-347 in FGFR2(IIIc) and Leu-
from that in FGFR1(IIIc) at two positions (Figure 5B).
98 in FGF2 and in possible steric clashes with FGF2.
Significantly, the residue corresponding to Val-317 in This prediction is consistent with the ligand binding
FGFR2 is an alanine in FGFR3, an amino acid with a properties of a double mutant KGFR, in which Tyr-345
smaller side chain than valine (Figure 5B). This will result and Gln-348 in KGFR were replaced by serine and iso-
in a weaker hydrophobic interaction with FGF2, affecting leucine as in FGFR2. This mutant receptor acquired sig-
the affinity of FGF2 toward FGFR3. Indeed, when these nificant binding affinity toward FGF2 as compared to
residues in FGFR3 were replaced with the correspond- the wild-type KGFR (Gray et al., 1995).
ing residues in FGFR1, the resultant FGFR3 mutant ex- Interestingly, mutation of an invariant asparagine in
hibited comparable FGF2 binding affinity (Chellaiah et the bF-bG loop (Asn-344 in KGFR) to an alanine abol-
al., 1999). ished the binding capacity of KGFR for all FGFs tested
Role of the bF-bG Loop (Gray et al., 1996). This result is consistent with the FGF-
Our structural data also identify the bF-bG loop in D3 FGFR structural data. In the FGF2-FGFR2 structure, the
as an important component in the regulation of FGF corresponding asparagine (Asn-346) makes two intra-
binding specificity. In the FGF2-FGFR2 structure, Ser- molecular hydrogen bonds with backbone atoms of Ile-
348 and Gly-349 (Figure 4A). These hydrogen bonds347 in FGFR2, located in the bF-bG loop, makes two
Crystal Structures of FGF-FGFR Complexes
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Figure 7. FGFR Mutations Implicated in Hu-
man Skeletal Disorders
The locations of the mutations in the human
FGFR2 gene that lead to skeletal disorders
are mapped onto a ribbon representation the
FGF2-FGFR2 structure. Side chains of the
residues are colored with respect to the type
of substitution. In yellow are mutations that
substitute a cysteine with another amino acid
or vice versa, resulting in the creation of un-
paired cysteines. In red are mutations that
are expected to destabilize the tertiary struc-
ture of D3 and thus disfavor the formation of
the correct intradomain disulfide bridge. In
green are mutations that are predicted to af-
fect ligand binding affinity or specificity. This
figure was created using the programs Mol-
script and Raster3D.
likely play an important role in maintaining the local fold FGFR Mutations Responsible for Human
Skeletal Disordersof the bF-bG loop.
Mutations in the extracellular domains of FGFR1 and
FGFR2 have been identified in patients with birth defects
involving craniosynostosis (premature fusion of the cra-The Role of the N-Terminal Segment of FGF
nial sutures), such as Pfeifer, Crouzon, Jackson-Weiss,In the crystal structures of free FGF1 and FGF2, residues
and Apert syndromes (reviewed by Naski and Ornitz,N-terminal to b1 are disordered (Eriksson et al., 1991;
1998; Burke et al., 1998). These mutations cluster inZhu et al., 1991; Blaber et al., 1996). However, in the
three regions: in the D2-D3 linker, in D3, and in thecrystal structures of the receptor-bound FGF1 and
linker connecting D3 to the transmembrane helix. TheseFGF2, several of these residues are ordered and in prox-
mutations can be subdivided into two classes: (1) substi-imity to D3 (Figures 4B and 4D). In the FGF2-FGFR2
tutions of a cysteine with another amino acid or vicestructure, the side chain of Phe-17 is located in a shallow
versa, creating unpaired cysteines, which lead to ligand-hydrophobic pocket that is formed by Pro-286, Ile-288,
independent dimerization and activation via formationand Val-280 in D3 (Figure 4B). Moreover, Phe-17 forms
of an intermolecular disulfide bond between receptorseveral hydrogen bonds via backbone atoms with Ser-
molecules, and (2) substitutions that do not involve cys-282 and Gln-285 in D3. Lys-18 in FGF2 also makes sev-
teines, which nevertheless must also result in constitu-eral hydrogen bonds with the side chains of Lys-279
tive receptor activation because they cause similar dis-and Glu-325 and with the backbone of Val-280 in D3
ease phenotypes as those mutations that create free(Figure 4B). In agreement with these structural observa-
cysteines. However, the precise molecular mechanismstions, it has been shown that a synthetic peptide con-
by which this class of mutations leads to receptor activa-sisting of residues 13±18 of FGF2 (prior to b1) competes
tion are less clear.
with binding of FGF2 to FGFR1 (Yayon et al., 1993).
To understand the molecular bases for the effects of
The amino acids 7NYKKPKL13 located at the junction these mutations on FGFR function, we have mapped
between the N-terminal segment and b1 in FGF1 have these mutations onto the FGF2-FGFR2 structure (Figure
been proposed to signal the nuclear accumulation of 7). Based on our structural data, we predict that many
FGF1 that occurs during sustained exposure of cells to mutations in D3, although not directly involving cyste-
FGF1 (Imamura et al., 1990). In the FGF1-FGFR1 struc- ines, could destabilize the tertiary structure of D3. This
ture, Tyr-8 located in this amino acid stretch inserts into would disfavor formation of the intradomain disulfide
a shallow hydrophobic pocket formed by the side chains bridge and increase the likelihood of disulfide bridging
of Val-279, Pro-285, and Ile-287. Thus, our structural between receptor molecules (Figure 7). This scenario
data provide a role for this region in receptor binding would likely apply to the mutation of Trp-290 to glycine
rather than a role in nuclear translocation. Deletion mu- or arginine. Trp-290 is located in the core of D3, adjacent
tagenesis experiments support this proposal. FGF1 mol- to the disulfide bridge, and replacement of this residue
ecules lacking this amino acid stretch have a 250-fold with either of the two amino acids would likely reduce
reduced ability to bind FGFR (Imamura et al., 1990). A the stability of D3 (Figure 7).
structure-based sequence alignment of FGFs (Figure 6) Mutations of two highly conserved residues in the D2-
reveals significant sequence diversity in the segment D3 linker of FGFR2, Ser-252 and Pro-253, are responsi-
N-terminal to b1, suggesting that this region may play ble for all known cases of Apert syndrome. Mutation of
the equivalent proline in FGFR1 (Pro-252) is found ina role in FGF binding specificity.
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dimensions a 5 62.55 AÊ , b 5 64.06 AÊ , c 5 64.14 AÊ , a 5 93.408, b 5some cases of Pfeifer syndrome. Based on these resi-
111.178, and g 5 97.188. There are two molecules of FGF1 and twodues's proximity to the ligand in the crystal structures,
molecules of FGFR1 in the asymmetric unit with a solvent contentwe would predict that these mutations result in aberrant
of z58%.
interactions between FGFRs and FGFs. Indeed, Ander- For crystallization of the FGF2-FGFR2 complex, 2 ml of protein
son et al. (1998) have shown that compared with wild- solution (10 mg/ml, 25 mM Tris-HCl [pH 7.5], and 150 mM NaCl)
was mixed with 2 ml of the crystallization buffer containing 10%±15%type FGFR2, mutant FGFR2 molecules bearing the Apert
PEG 4000, 10% isopropanol, and 0.1 M HEPES-NaOH (pH 7.5). Themutations exhibit a selective increase in affinity toward
FGF2-FGFR2 crystals belong to the triclinic space group P1 withFGF2, leading to enhanced signaling where availability
unit cell dimensions a 5 72.20 AÊ , b 5 71.68 AÊ , c 5 90.92 AÊ , a 5of ligand is limiting.
90.538, b 5 89.988, and g 5 89.998. There are four molecules of FGF2
As described earlier, the amino acid stretch between and four molecules of FGFR2 in the unit cell with a solvent content
bC9 and bE plays a critical role in determining specificity. of z58%.
Diffraction data were collected from flash-frozen (in a dry nitrogenAsp-321 makes three hydrogen bonds with FGF2 (Figure
stream using mother liquor containing 10% glycerol as cryo-pro-4C). Replacement of Asp-321 with alanine, which is de-
tectant) crystals on either an R-Axis IV image plate detector (FGF1-tected in some cases of Pfeifer syndrome, will therefore
FGFR1) or on a CCD detector (FGF2-FGFR2) at beamline X4A atreduce the affinity of FGF2 toward FGFR2. However, it
the National Synchrotron Light Source, Brookhaven National Labo-
is conceivable that this substitution could increase the ratory. All data were processed using DENZO and SCALEPACK
affinity of FGFR2 for other members of the FGF family. In (Otwinowski, 1993).
summary, the large variety of gain-of-function mutations
detected in human skeletal disorders activate FGFRs Structure Determination and Refinement
either by promoting FGFR dimerization or by altering The structure of FGF1-FGFR1 was determined by molecular replace-
ment using the program AmoRe (Navaza, 1994) and the structuresligand-receptor specificity.
of FGF1 (2AFG; Blaber et al., 1996) and telokin (1TLK; Holden et al.,The FGF-FGFR signal transduction system is an es-
1992) as search models. Homology models for D2 and D3 of FGFR1sential component of a large number of biological pro-
were constructed from the telokin structure. A molecular replace-
cesses in humans such as embryonic development, ment solution was found for two copies of FGF1 and two copies
wound healing, and angiogenesis. Rational design of each of D2 and D3. Simulated annealing and positional/B factor
both antagonists and agonists for FGF actions is an refinement were performed using CNS (BruÈ nger et al., 1998). Bulk
solvent and anisotropic B factor corrections were applied. Tightattractive and challenging avenue for future research,
noncrystallographic symmetry restraints were imposed throughoutand the structural data presented here should acceler-
the refinement for the backbone atoms of FGF1, D2, and D3. Theate this process. Antagonists of FGF signaling could
r.m.s.d for Ca atoms between the two copies of FGF1, D2, or D3 is
potentially be used not only for treatment of human 0.01 AÊ . Model building into 2Fo-Fc and Fo-Fc electron density maps
skeletal disorders but also for blocking angiogenesis in was performed with program O (Jones et al., 1991). The atomic
pathological conditions such as diabetic retinopathy model includes FGF1 residues 8±138 and FGFR1 residues 147±359,
except residues 294±305 (bC-bC9 loop in D3) and 315±323 (segmentand tumor neovascularization. Conversely, agonists of
between bC9 and bE in D3), which are disordered. The average BFGF could be used to induce angiogenesis in angina
factor is 31.8 AÊ 2 for FGF1 molecules, 28.6 AÊ 2 for FGFR1 molecules,and stroke as well as to accelerate wound healing.
and 64.9 AÊ 2 for sulfate ions.
A molecular replacement solution for the four FGF2-FGFR2 com-
Experimental Procedures plexes in the asymmetric unit was found with AmoRe (Navaza, 1994)
using the structure of FGF2-FGFR1 (1CVS; Plotnikov et al., 1999)
Crystallization and Data Collection as the search model. Tight noncrystallographic symmetry restraints
DNA fragments encoding residues 142 to 365 of FGFR1 and 147 to were imposed throughout the refinement for the backbone atoms
366 of FGFR2 were amplified by polymerase chain reaction (PCR) of FGF2, D2, and D3. The atomic model includes FGF2 residues
and subcloned into the bacterial expression vector pET-28a using 16±145 and FGFR2 residues 148±365, four sulfate ions, and 263
NcoI and HindIII cloning sites and transfected into the bacterial
water molecules. In all four FGFR2 molecules, residues 295±306
strain BL21(DE3). Cells were induced with IPTG for 5 hr, centrifuged,
(bC-bC9 loop in D3) are disordered. The average B factor is 40.5 AÊ 2
and the bacterial pellet was lysed in 25 mM K-Na phosphate buffer
for FGF2 molecules, 37.7 AÊ 2 for FGFR2 molecules, 73 AÊ 2 for sulfate
(pH 7.5) containing 150 mM NaCl, 2 mM EDTA, and 10% glycerol
ions, and 32.6 AÊ 2 for water molecules.
using a French press. Following centrifugation, the pellets con-
taining primarily FGFR1 or FGFR2 were dissolved in 6 M guanidinium
Acknowledgmentshydrochloride and 10 mM DTT in 100 mM Tris-HCl buffer (pH 8.0).
The solubilized FGFR1 and FGFR2 proteins were refolded by dialysis
We thank A. V. Eliseenkova for excellent technical assistance, C.against 25 mM HEPES buffer (pH 7.5) containing 150 mM NaCl, 10%
Ogata for synchrotron beamline assistance, T. Cardozo for help inGlycerol, and 1 mM L-Cysteine. The refolded FGFR1 and FGFR2
homology modeling, and B. K. Yeh for help in figure preparation.proteins were loaded onto heparin sepharose columns on which
FGF1 or FGF2 had previously been immobilized. The FGF1-FGFR1 S. R. H. is a recipient of a Kimmel Scholar Award from the Sidney
and FGF2-FGFR2 complexes were then eluted from the heparin Kimmel Foundation for Cancer Research. Beamline X4A at the Na-
sepharose column with 25 mM Tris-HCl buffer (pH 7.5) containing tional Synchrotron Light Source, a Department of Energy facility, is
1.5 M NaCl. The FGF1-FGFR1 and FGF2-FGFR2 complexes were supported by the Howard Hughes Medical Institute. Coordinates
concentrated using Centricon 10 (Amicon) filters and further purified will be deposited in the Protein Data Bank.
by size exclusion chromatography on a Superdex 200 (Pharmacia)
column equilibrated with 25 mM Tris-HCl buffer (pH 7.5) containing
Received January 11, 2000; revised April 14, 2000.
1.5 M NaCl. Both of the complexes migrated at a position consistent
with the formation of 1:1 FGF:FGFR complexes.
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Protein Data Bank ID Codes
The structural coordinates for the FGF1-FGFR1 and FGF2-FGFR2
structures have been deposited in the Protein Data Bank under ID
codes 1EVT and 1EV2, respectively.
